N psoriasis patient blood. J Invest Dermatol 134(12):2990sirtuininhibitor993. 41. Papp K, et al. (2014) Safety and efficacy of brodalumab for psoriasis following 120 weeks of therapy. J Am Acad Dermatol 71(6):1183sirtuininhibitor190.e3. 42. Johansen C, et al. (2009) Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol 160(2):319sirtuininhibitor24. 43. Ramirez-Carrozzi V, et al. (2011) IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol 12(12):1159sirtuininhibitor166. 44. Gaffen SL, Jain R, Garg AV, Cua DJ (2014) The IL-23-IL-17 immune axis: From mechanisms to therapeutic testing. Nat Rev Immunol 14(9):585sirtuininhibitor00.E5832 | www.pnas.org/cgi/doi/10.1073/pnas.Johansen et al.45. Ha HL, et al. (2014) IL-17 drives psoriatic inflammation through distinct, target cell-specific mechanisms. Proc Natl Acad Sci USA 111(33):E3422 3431. 46. S der SU, Paun A, Ha HL, Johnson PF, Siebenlist U (2012) CIKS/Act1-mediated signaling by IL-17 cytokines in context: Implications for how a CIKS gene variant may perhaps predispose to psoriasis. J Immunol 188(12):5906sirtuininhibitor914. 47. Chang SH, Park H, Dong C (2006) Act1 adaptor protein is definitely an quick and vital signaling element of interleukin-17 receptor. J Biol Chem 281(47):35603sirtuininhibitor5607. 48. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G (1996) Immune and inflammatory responses in TNF alpha-deficient mice: A essential requirement for TNF alpha in theformation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and within the maturation in the humoral immune response. J Exp Med 184(4): 1397sirtuininhibitor411. 49. Kragballe K, Desjarlais L, Marcelo CL (1985) Elevated DNA synthesis of uninvolved psoriatic epidermis is maintained in vitro. Br J Dermatol 112(three):263sirtuininhibitor70. 50. Hildebrand DG, et al. (2013) IB is actually a transcriptional essential regulator of CCL2/MCP-1. J Immunol 190(9):4812sirtuininhibitor820. 51. Ghoreschi K, et al. (2011) Fumarates enhance psoriasis and many sclerosis by inducing sort II dendritic cells. J Exp Med 208(11):2291sirtuininhibitor303.Johansen et al.PNAS | Published on the web October 12, 2015 | EIMMUNOLOGY AND INFLAMMATIONPNAS PLUS
HHS Public AccessAuthor manuscriptN Engl J Med. Author manuscript; accessible in PMC 2016 June 17.Published in final edited form as: N Engl J Med. 2015 December 17; 373(25): 2425sirtuininhibitor437. doi:ten.1056/NEJMoa1509388.G-CSF Protein site Author Manuscript Author Manuscript Author Manuscript Author ManuscriptIbrutinib as Initial Therapy for Individuals with Chronic Lymphocytic LeukemiaJan A.Delta-like 4/DLL4 Protein Synonyms Burger, M.PMID:25818744 D., Ph.D., Alessandra Tedeschi, M.D., Paul M. Barr, M.D., Tadeusz Robak, M.D., Ph.D., Carolyn Owen, M.D., Paolo Ghia, M.D., Ph.D., Osnat Bairey, M.D., Peter Hillmen, M.B., Ch.B., Ph.D., Nancy L. Bartlett, M.D., Jianyong Li, M.D., David Simpson, M.B., B.S., Sebastian Grosicki, M.D., Ph.D., Stephen Devereux, F.R.C.P., F.R.C.Path., Ph.D., Helen McCarthy, F.R.C.P., F.R.C.Path., Ph.D., Steven Coutre, M.D., Hang Quach, M.B., B.S., M.D., Gianluca Gaidano, M.D., Ph.D., Zvenyslava Maslyak, M.D., Don A. Stevens, M.D., Ann Janssens, M.D., Fritz Offner, M.D., Ph.D., JisirtuininhibitorMayer, M.D., Michael O’Dwyer, M.D., Andrzej Hellmann, M.D., Ph.D., Anna Schuh, M.D., Ph.D., Tanya Siddiqi, M.D., Aaron Polliack, M.D., Constantine S. Tam, M.B., B.S., Deepali Suri, M.S., Mei Cheng, Ph.D., Fong Clow, Sc.D., Lori Types, M.D., Danelle F. James, M.
